REG - Eco Animal Health Gp - Capital Markets Day Events

ECO Animal HealthAnnouncement

09/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231109:nRSI8683Sa&default-theme=true

RNS Number : 8683S  Eco Animal Health Group PLC  09 November 2023

9 November 2023

ECO Animal Health Group plc

Capital Markets Day Events - R&D Portfolio

ECO Animal Health Group plc (AIM: EAH), a leader in the development,
registration and marketing of pharmaceutical products for global animal health
markets, is pleased to announce that it will be hosting two Capital Markets
events focused on progress and developments in the Company's Research &
Development portfolio today, Thursday 9 November 2023.

No new material information will be disclosed at the events.

For further information please contact:

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)

 IFC Advisory                                                   020 3934 6630

 Graham Herring

 Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 Sam Butcher

 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska

 Carlo Spingardi

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products
for livestock. Our business strategy is to generate shareholder value by
achieving the maximum sales potential from the existing product portfolio
whilst investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZMGMGLGGFZG